Benefits
ONLY Omega-3 Crossing Blood-Brain Barrier via Mfsd2a
Lysoveta is the only known omega-3 form proven to cross the blood-brain barrier through the Mfsd2a transporter — direct brain delivery of essential fatty acids.
Targeted Brain Omega-3 Delivery
Delivers essential omega-3 fatty acids DHA and EPA directly to the brain along with critical phospholipids and choline.
LPC-EPA Brain Conversion to DHA
Research indicates LPC-EPA is efficiently converted into DHA in the brain — enhancing brain DHA levels.
Brain Function and Cognitive Support
Supports brain function, cognitive performance, and overall brain health applications.
Patented Technology
Aker BioMarine's patented LPC extraction technology — proprietary breakthrough.
2025 CMA Innovation Award
Innovation Winner at 2025 Complementary Medicines Australia Industry Awards — industry recognition.
Choline + Phospholipid Delivery
Beyond omega-3, Lysoveta delivers choline and phospholipids — complete brain nutrition package.
Mechanism of action
Mfsd2a Transporter BBB Crossing
Mfsd2a (Major Facilitator Superfamily Domain Containing 2A) is specific transporter at blood-brain barrier for LPC-bound fatty acids; conventional triglyceride-bound omega-3s do NOT cross BBB efficiently via this route.
LPC vs Triglyceride Forms
Lysophosphatidylcholine (LPC) is phospholipid form with single fatty acid attached; uniquely transported across BBB; standard fish/krill oil omega-3s typically triglyceride-bound; do not access this transport pathway.
Brain DHA Synthesis from EPA
Once LPC-EPA crosses BBB, it can be converted to DHA in brain — addresses brain DHA needs even from EPA precursor.
Comprehensive Brain Nutrition
Delivers EPA, DHA, choline, phospholipids — all critical brain nutrients in one ingredient.
Clinical trials
Aker BioMarine clinical evaluation of Lysoveta LPC-bound omega-3 brain delivery and applications.
Adults across cognitive applications.
Established Mfsd2a-mediated BBB crossing; brain function applications.